Group 1 - Stroke has a high incidence and disability rate, making it a leading health threat, despite advancements in acute vascular recanalization techniques [1] - Many stroke patients suffer from severe neurological deficits, leading to long rehabilitation processes and significant burdens on families and society [1] - Regenerative medicine, particularly stem cell therapy, offers new hope for addressing the global challenge of nerve repair [1] Group 2 - A live session featuring Dr. Huo Xiaochuan, a neurosurgeon from Capital Medical University, and Li Li, founder and chairman of Senpuri (Beijing) Cell Technology Co., will discuss the scientific principles, clinical evidence, safety boundaries, and future prospects of stem cell therapy [1] - Dr. Huo Xiaochuan is recognized for his contributions to stroke intervention and has received the Wang Zhongcheng Annual Young Physician Award [1]

Core Insights - ONWARD Medical has completed a financing round exceeding €50 million (approximately 410 million RMB) to support its mission of restoring movement to spinal cord injury patients [2] - The company has transitioned from a research-focused entity to a commercial enterprise, with plans to expand its ARC-EX system and advance clinical research for the next-generation ARC-IM system [3] Product Development - ONWARD's product ecosystem includes three core products: ARC-EX, ARC-IM, and ARC-BCI, which together cover the full spectrum from non-invasive rehabilitation to closed-loop implants [5][7] - The ARC-EX system is a transcutaneous electrical nerve stimulation device approved in the U.S. for restoring upper limb function post-spinal cord injury, while ARC-IM is an implantable system for more severe motor impairments [8] Technological Framework - ONWARD is developing a closed-loop system that integrates neural stimulation, motor feedback, and brain-computer interfaces (BCI) to create a comprehensive rehabilitation solution [8] - The company has completed five successful implant surgeries of the brain-spinal cord closed-loop system, demonstrating the potential for neural plasticity to be reactivated [9] Strategic Partnerships - Ottobock, a leading prosthetics and orthotics company, has significantly invested in ONWARD, indicating a strategic shift towards neuro-rehabilitation technologies [10][12] - This partnership is seen as a critical component in Ottobock's transition towards integrating neural reconnection with prosthetic solutions [12] Market Context - In China, the spinal cord injury patient population exceeds 1 million, with approximately 60,000 new cases annually, highlighting a growing need for effective neuro-rehabilitation technologies [13] - ONWARD's approach contrasts with many Chinese BCI companies that focus on human-machine interaction rather than functional restoration, positioning ONWARD's model as a potential reference for domestic development [13] Regulatory Environment - ONWARD's ARC-BCI has received FDA breakthrough device designation, facilitating a more streamlined regulatory pathway for its neuro-rehabilitation products [14] - The company is establishing a clear validation system through multi-center clinical trials, creating a data loop that supports its commercial strategy [16] Future Outlook - The recent financing marks a significant step for ONWARD, transitioning from technical validation to building a sustainable commercial framework in the neuro-rehabilitation sector [18] - The integration of capital and engineering efforts is expected to redefine the human movement system, emphasizing the importance of restoring autonomy to patients [19]